ArticleJournal of chemical information and modeling2026
Unveiling the KRAS Relationship between Affinity and Dynamics: A Molecular Simulations Study.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kirsten rat sarcoma virus protein (KRAS) is one of the most important targets in current drug discovery. Its intrinsic properties, including a high structural flexibility and a shallow polar pocket, make KRAS extremely difficult to target. In fact, for a long time it was considered undruggable. A better understanding of its structure and dynamics will help to advance drug discovery efforts. KRAS is a GTPase, which is highly relevant for the growth, proliferation, and differentiation of cells. Several oncogenic mutations have been identified, suggesting that KRAS could be an excellent target in the fight against cancer. In this work, we use molecular dynamics simulations to highlight the challenges of this protein in computational drug design. We start from a characterization of the structural flexibility and the diversity in observed molecular interactions. Then we quantify the thermodynamic reasons for the increased stability of the G12C mutant in the active, GTP-bound state. For this we use two thermodynamic cycles and find that the alchemical mutation leads to internally consistent results, in agreement with the biological observations. Furthermore, we explore the use of Accelerated Enveloping Distribution Sampling (A-EDS) to efficiently screen a small set of fragments with the strongest binding affinity. The screening mode of A-EDS already allows for the identification of the most favorable candidate molecules. Subsequently, further optimization of the A-EDS parameters facilitates a quantification of the relative binding affinities in terms of free energies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.